Details of the Drug Combinations

General Information of This Drug (ID: DMJ18YL)

Drug Name

Secnidazole DMJ18YL

Synonyms

3366-95-8; Secnidazol; Secnidazolum; Flagentyl; Secnidazolum [INN-Latin]; Solosec; RP 14539; Secnidazol [INN-Spanish]; PM 185184;Secnidazole (Flagentyl); SYM-1219; EINECS 222-134-0; seknidazol; MLS000559043; PM-185184; NCGC00095158-01; SMR000149359; RP-14539

Indication

Disease Entry	ICD 11	Status	REF
Amoebiasis	1A36	Approved	[1]
Bacterial vaginosis	MF3A	Approved	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

2 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Secnidazole + Idarubicin	DC52HM3	Idarubicin	Glioblastoma? (Cell Line: T98G)	[3]
Secnidazole + Ruxolitinib	DCQ7GN6	Ruxolitinib	Hodgkin lymphoma (Cell Line: L-1236)	[4]
------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
3	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
4	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976